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Abstract
Background: Persistent dysphagia following primary chemoradiation (CRT) for head and neck cancers can have a
devastating impact on patients’ quality of life. Single arm studies have shown that the dosimetric sparing of critical
swallowing structures such as the pharyngeal constrictor muscle and supraglottic larynx can translate to better
functional outcomes. However, there are no current randomised studies to confirm the benefits of such swallow
sparing strategies. The aim of Dysphagia/Aspiration at risk structures (DARS) trial is to determine whether reducing
the dose to the pharyngeal constrictors with dysphagia-optimised intensity- modulated radiotherapy (Do-IMRT) will
lead to an improvement in long- term swallowing function without having any detrimental impact on disease-
specific survival outcomes.
Methods/design: The DARS trial (CRUK/14/014) is a phase III multicentre randomised controlled trial (RCT) for
patients undergoing primary (chemo) radiotherapy for T1-4, N0-3, M0 pharyngeal cancers. Patients will be
randomised (1:1 ratio) to either standard IMRT (S-IMRT) or Do-IMRT. Radiotherapy doses will be the same in both
groups; however in patients allocated to Do-IMRT, irradiation of the pharyngeal musculature will be reduced by
delivering IMRT identifying the pharyngeal muscles as organs at risk. The primary endpoint of the trial is the
difference in the mean MD Anderson Dysphagia Inventory (MDADI) composite score, a patient-reported outcome,
measured at 12 months post radiotherapy. Secondary endpoints include prospective and longitudinal evaluation of
swallow outcomes incorporating a range of subjective and objective assessments, quality of life measures, loco-
regional control and overall survival. Patients and speech and language therapists (SLTs) will both be blinded to
treatment allocation arm to minimise outcome-reporting bias.
Discussion: DARS is the first RCT investigating the effect of swallow sparing strategies on improving long-term
swallowing outcomes in pharyngeal cancers. An integral part of the study is the multidimensional approach to
swallowing assessment, providing robust data for the standardisation of future swallow outcome measures. A
translational sub- study, which may lead to the development of future predictive and prognostic biomarkers,
is also planned.
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Background
Cancer of the pharynx affects around 3000 patients in
the UK annually [1], with a majority of cases caused by
infection with human papillomavirus (HPV) [2]. For
most newly diagnosed patients organ-preserving CRT or
radiation alone is the treatment of choice. A significant
proportion of survivors, however, subsequently suffer
from long-term treatment- related toxicities such as
xerostomia and dysphagia. Improving such functional
outcomes is pivotal in an era where younger and health-
ier patients are increasingly cured of their HPV- driven
tumours with CRT [3], only to be exposed to decades of
debilitating radiation- induced morbidity resulting in an
adverse impact on health- related quality of life (HR-
QoL). There has been a renewed focus recently to ad-
dress this issue, with the required impetus to achieve
this goal facilitated by the widespread availability of ad-
vanced radiation delivery techniques.
Dysphagia following CRT represents a substantial
problem, with nearly 50 % of patients identifying it as a
distressing symptom following radiation treatment [4].
Radiation dose to critical structures involved in the
swallowing mechanism and post- radiation pharyngo-
oesophageal strictures contribute significantly to poor
long-term function. A major clinical consequence of
swallowing dysfunction is aspiration and related pneu-
monia [5–8]. This is typically under-reported in most
head and neck cancer (HNC) trials, where assessments
are undertaken only at the onset of clinical symptoms
only, thereby failing to detect the silent aspirators [9].
Dietary modifications, nutritional deficiencies, and pro-
longed feeding tube dependence [10, 11] are usually a
consequence of persistent dysphagia, resulting in poor
social interactions along with lifestyle alterations for
both patients and their carers/family members [12]. Fi-
nally, late radiation- associated dysphagia is a distinct
entity characterised by a delayed onset of swallowing
dysfunction in combination usually with lower cranial
neuropathy, which invariably leads to aspiration pneu-
monia in a majority with subsequent lifelong depend-
ence on a feeding tube [13].
It is evident that dysphagia following CRT has a nega-
tive impact on a patient’s physical, social and emotional
state. Yet, consistent, prospective evaluation of all three
states of swallowing outcomes is conspicuous by its ab-
sence in most HNC studies reporting on post- treatment
functional status [14]. Frequently used subjective tools,
such as patient- reported outcomes and clinician- rated
scores, provide invaluable information about HR-QoL
and represent a quick, cost effective method of reporting
swallowing outcomes. Toxicity reporting measures are,
however, subject to significant inter-observer variability
[15–17] and are also insensitive in quantifying functional
abnormalities such as the risk of aspiration, which is
detected using instrumental swallowing assessments
such as videofluoroscopy (VF) or Fibreoptic Endoscopic
Evaluation of Swallowing (FEES). Such variations in out-
come reporting result in different normal tissue compli-
cation (NTCP) models predicted for dysphagia in the
same patient population [18]. Lack of a comprehensive
swallowing assessments necessitates caution in interpret-
ation of the reported outcomes; particularly as the true
burden of dysphagia- related morbidity might not have
been accurately determined.
The introduction of intensity- modulated radiotherapy
(IMRT) in HNC has improved HR-QoL by improving
salivary function [19], and can reduce the delivered dose
to critical swallowing structures [20]. In a pioneering
study, a strong association was established between ir-
radiation of the pharyngeal constrictor muscle (PCM),
glottis and supraglottic larynx (SGL) and subsequent
swallowing dysfunction [20]. To improve functional out-
comes, it is imperative to safely spare these dysphagia/
aspiration at risk structures (DARS). Numerous planning
studies have confirmed a significant relationship be-
tween irradiation of various swallowing structures and
persistent dysphagia [11, 21–29]; with the mean dose to
the PCM a strong predictor of swallowing impairment
in a systematic review [30]. Despite this, there is signifi-
cant uncertainty regarding the clinically relevant struc-
tural and dosimetric predictors of long-term functional
impairment. Differences in influential variables such as
primary tumour location, tumour stage, use of concomi-
tant chemotherapy, fractionation schedules, and in pri-
mary endpoints and target volume definition limit the
conclusions that can be drawn. Furthermore, small sam-
ple sizes together with the retrospective nature of most
studies and inconsistent swallow outcome recording
affect the robustness of the reported results.
Promising results have emerged from prospective non-
randomised, oropharyngeal cancer only studies. Feng
et al. evaluated the efficacy of swallow- sparing chemo-
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IMRT in 73 patients with stage III/IV oropharyngeal
cancers [31]. The IMRT technique involved sparing the
PCM and SGL in the region of the rarely involved
medial retropharyngeal lymph nodes (RPN), delivered by
setting a dosimetric constraint of <50 Gy. Mean doses of
48 Gy and 42 Gy were achieved for the spared parts of
PCM and SGL respectively; with corresponding mean
doses to the entire organs of 58 Gy and 48 Gy. Crucially,
this dosimetric sparing did not increase the risk of loco-
regional recurrence, with no relapses observed within or
near the spared structures. Long-term swallowing out-
comes with this novel IMRT approach were only slightly
worse compared to baseline, suggesting potential func-
tional improvements. Subsequent dosimetric analysis
revealed a significant association between worsened
swallowing outcomes and mean doses to the entire PCM
and its individual parts, particularly the superior con-
strictor, SGL and oesophagus [18]. Another smaller
phase II study in oropharyngeal cancer has also demon-
strated improved objective function by sparing the
anterior oral cavity and the upper pharyngeal muscula-
ture [32].
Validated predictive models for RTOG ≥ grade 2 dys-
phagia at 6 months in a heterogeneous group of HNC
patients treated with (chemo) radiation have also been
developed by a consortium of Dutch radiation oncolo-
gists. Initial planning work found the superior PCM and
SGL to be the strongest dosimetric predictors, with a
subsequent in-silico study demonstrating likely improve-
ments in the clinician- rated scores by safely minimising
as much as possible the dose to the two swallowing or-
gans at risk (OAR) without compromising target cover-
age. Finally, patients followed up prospectively showed
clinically relevant functional improvements with this
strategy [33–36]. As mentioned previously, the use of
only a clinician-rated score to develop their model is a
limitation of this study.
Rationale for the DARS trial
Despite the available published literature regarding opti-
misation of radiotherapy techniques to improve long-
term swallow function, the question of whether function-
sparing IMRT techniques truly improve function and HR-
QoL remains unanswered. In a world of evidence-based
medicine, outcomes from single-arm studies confirming
the existence of a strong association between dosimetric
sparing of DARS and functional improvement are insuffi-
cient to alter current standards-of-care. Results from these
studies strengthen the rationale to explore this important
question within the context of a randomised controlled
trial (RCT). The DARS trial (CRUK/14/014) was con-
ceived primarily to answer this vital patient- centred ques-
tion of whether the implementation of Do-IMRT in
pharyngeal cancers will lead to a subjective improvement
of swallow function.
In order to achieve satisfactory long-term swallowing
function, it is necessary to acknowledge that a ‘one size
fits all’ model to develop a swallow-sparing strategy for
all H&N sub sites is unlikely to be successful. Although
attempts should be directed to reducing the radiation
dose to all swallowing OARs as much as clinically ac-
ceptable, sparing the swallowing structure in close prox-
imity to the primary tumour should be a priority as it is
a key determinant of subsequent poor functional out-
come [21]. Therefore, establishing different dose con-
straints for the swallowing OARs, dependent on the
location of the primary tumour, is essential. Evidence to
date, confirms that a strong and clinically relevant cor-
relation exists between PCM irradiation and the devel-
opment of persistent dysphagia in pharyngeal cancers.
Methods/design
Study design
DARS is a parallel-group, multicentre phase III RCT,
with blinded assessments of key outcome measures, in
patients undergoing radical primary chemoradiation or
radiation alone for pharyngeal tumours. Suitable patients
will be randomised to either S-IMRT or Do-IMRT
(Fig. 1). Radiotherapy dose and fractionation will be the
same in both treatment groups; in the Do-IMRT arm,
the dose to the PCM will be reduced by identifying it as
an organ at risk, thereby optimising the treatment plan
to meet specified dose constraints.
The trial opened to recruitment in June 2016 and is
expected to recruit in approximately 20–25 UK centres.
Patient population
Patients should satisfy all the inclusion criteria and meet
none of the exclusion criteria specified in Table 1 to be
eligible for the trial. In brief, patients will have biopsy
proven, pharyngeal cancers that will be treated with bi-
lateral neck irradiation. The use of both prophylactic
and reactive feeding tube insertions is acceptable, though
patients would be encouraged to keep swallowing (even
if very limited amounts) for the duration of treatment.
Study objectives and endpoints
The primary objective of the DARS trial is to determine
whether reducing the radiation dose to DARS using Do-
IMRT, improves swallowing function compared to S-
IMRT in pharyngeal cancer patients treated with radical
chemoradiation or radiation alone. The impact of the
dosimetric sparing achieved with Do-IMRT on late swal-
lowing function will be evaluated by a patient-reported
outcome (PRO) using the MDADI. The difference in the
mean MDADI composite score at 12 months after
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treatment completion between randomised treatment
groups forms the primary endpoint of the trial.
Secondary objectives are to:
1. Investigate the longitudinal pattern of patient-
reported swallowing function up to 2 years post-
radiotherapy treatment using the MDADI;
2. Investigate the impact of using Do-IMRT on
(i) normalcy of diet and public eating using the PSS-
HN scale;
(ii) swallowing performance using the 100 mL
Water Swallow Test and VF examination (subset
of centres only);
(iii) acute and late toxicity
(iv) duration of feeding tube use;
3. Assess patient-reported QoL and priority concerns
using the UW-QoL questionnaire (v.04);
4. Compare cancer- related outcomes according to
radiotherapy technique used, including resection
rates, location and timing of loco-regional recur-
rence and overall survival.
Registration/randomisation
The trial has a two-stage entry process of registration and
randomisation. Randomisation only occurs following tar-
get outlining, ensuring consistency across both the experi-
mental and standard treatment volumes by avoiding any
potential bias that could be introduced by the clinician
during delineation. Additionally, patients and SLTs will be
blinded to the treatment allocation to avoid bias during
assessments. This is particularly relevant in a trial of this
nature where a majority of endpoints rely on a combin-
ation of patient- reported outcomes and SLT- led
evaluations.
Fig. 1 TRIAL SCHEMA
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Patients will be randomised between the 2 treat-
ments on a 1:1 basis using the method of minimisa-
tion with a random element. Randomisation will be
performed centrally by the Institute of Cancer Re-
search Clinical Trials Statistics Unit (ICR-CTSU). Pa-
tients will be stratified prior to randomisation by
centre, use of induction and concomitant chemother-
apy, tumour site (incorporating HPV status for oro-
pharyngeal tumours) and American Joint Committee
on Cancer (AJCC) tumour stage.
Chemotherapy
Induction chemotherapy is optional and will follow the
centres’ standard policy; a maximum of 3 cycles of
platinum-based chemotherapy can be administered prior
to radiotherapy. The principal investigator of each centre
will be expected to define their use of induction chemo-
therapy by TNM stage and tumour site prior to the trial
opening.
Concomitant chemotherapy is recommended for all
patients, unless there is a contraindication, in which
case radiotherapy alone will be permitted. The stand-
ard regimen will be cisplatin 100 mg/m2 administered
on day 1 and day 29 of the radiotherapy schedule; al-
ternatively 50 mg/m2 on days 1 and 2 repeated again
on days 29 and 30 will be acceptable. Carboplatin
(AUC 5) can be substituted if patients have an exist-
ing co-morbidity or subsequently develop cisplatin-
related toxicity.
Radiotherapy
Patients in both treatment groups will receive 65Gy
in 30 fractions to the primary and nodal tumour
(PTV_6500) and 54Gy in 30 fractions (PTV_5400) to
the areas considered at risk of harbouring micro-
scopic disease. Treatment will be delivered by a var-
iety of IMRT techniques. Patients in the S-IMRT
control group will receive the current standard- of-
care radiation planning, whereas PCM irradiation will
be reduced by introducing it as an OAR in the treat-
ment planning objectives of patients allotted to the
Do-IMRT arm.
Treatment verification will include the following as a
minimum: orthogonal kilovoltage (KV) or megavoltage
(MV) isocentre images, or cone beam CT images, taken
on days 1–3 and then weekly. Any treatment gaps will
be managed as per the Royal College of Radiologists
guidelines for Category 1 patients, aiming to complete
radiotherapy within 6 weeks.
Target volume delineation
DARS has adopted a volumetric approach to define the
target volumes. Findings at the time of endoscopy along
with pre-therapy imaging will be used to aid accurate
delineation of the primary tumour. Two clinical target
volumes (CTV) will be defined and edited to exclude
natural barriers to disease spread. CTV_6500 will in-
clude the primary and nodal gross tumour volume
(GTV) with a 1 cm isotropic margin while the prophy-
lactic CTV_5400 will include the remainder of the in-
volved subsite and nodal levels at risk of microscopic
disease. Corresponding planning target volumes (PTVs)
will be grown with 3–5 mm margins, according to the
practice of individual centres. CT delineation of nodal
levels will follow the recently updated outlining guide-
lines [37].
The superior and middle constrictors will be con-
toured as one structure (SMPCM) in the trial with
the inferior PCM (IPCM) delineated as a separate
Table 1 Inclusion and exclusion criteria for patient recruitment
in the DARS trial
Inclusion Criteria:
• Aged 18 or above;
• Any patient undergoing radiotherapy for HNC in the oropharynx or
hypopharynx. Patients with tumour at other sites where radical
radiotherapy dose is to be delivered to the pharyngeal constrictors
may also be eligible;
• Stage T1-4, N0-3, M0 disease; this will be mostly histologically con-
firmed squamous cell carcinoma but other histological types may be
eligible;
• Radiotherapy with concomitant chemotherapy (unless contraindicated)
is the planned treatment;
• Creatinine clearance (≥50 mL/min prior to starting chemotherapy); not
applicable for patients receiving radiotherapy alone;
• WHO performance status 0 or 1;
• Available to attend long term follow- up;
• Adequate cognitive ability to complete the MD Anderson Dysphagia
Inventory (MDADI), University of Washington Quality of Life (UW-QoL)
v.04 questionnaire and Performance Status Scale for Head & Neck
Cancer (PSS-HN) assessments;
• Written informed consent.
Exclusion Criteria:
• Documented evidence of pre-existing swallowing dysfunction (not re-
lated to HNC);
• Previous radiotherapy to the head and neck region;
• Posterior pharyngeal wall, post- cricoid and retropharyngeal lymph
node involvement;
• Lateralised tumours, requiring unilateral irradiation
• Major head and neck surgery (excluding biopsies/tonsillectomy);
• Current/previous tracheostomy placement;
• Previous or concurrent illness, which in the investigator’s opinion
would interfere with completion of therapy, trial assessments or
follow-up;
• Any invasive malignancy within previous 2 years (other than non-
melanomatous skin carcinoma or cervical carcinoma in situ).
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structure. Outlining for the PCM is based on the
published contouring guidelines defined by Christia-
nen et al. in conjunction with the atlas produced for
the Post-operative adjuvant treatment for HPV posi-
tive tumours (PATHOS; NCT02215265) trial [38, 39].
Other OARs will include the spinal cord, brainstem
and the parotid glands.
Do-IMRT
The experimental Do-IMRT technique aims to spare the
PCM lying outside the high dose CTV. For oropharyn-
geal primaries, mandatory mean dose constraints of
<50 Gy to the volume of SMPCM lying outside
CTV_6500 (PlanSMPCM) together with an optimal
mean dose constraint of <20 Gy to the volume of IPCM
lying outside CTV_6500 (PlanIPCM) have been defined.
Likewise, for hypopharyngeal tumours, mandatory and
optimal mean dose constraints of <50 Gy and <40 Gy
have been set for PlanIPCM and PlanSMPCM
respectively.
Crucially, it is important to note that although the
PCM will overlap with the PTVs, there will be no spar-
ing of the constrictor muscles that lie within the
PTV_6500.
Planning objectives will be prioritised in the following
order: critical organ constraints (spinal cord and
brainstem); PTV_6500 coverage; constrictor con-
straints; PTV_5400 coverage; parotid gland constraints
and other non-specified normal tissue.
Assessments
Toxicity and response assessments NCI CTCAE v4.0
will be used to assess acute toxicity data that will be
collected weekly during radiotherapy, and at week 1–
4 and 8 after treatment completion. Late toxicity will
be scored using both NCI CTCAE v4.0 and LENT
SOMA scoring systems. Clinical assessments will be
made at 6 weeks, and 6, 12, 18 and 24 months after
completion of treatment as a minimum. Additional
investigations will be requested if clinically indicated.
Imaging response will be carried out at 3 months
after radiotherapy and reported as per RECIST criteria
v1.1. Patients found to have persistent cervical lymph-
adenopathy will proceed to neck dissection. Late tox-
icity and survival data will be collected at 3, 6, 12, 18
and 24 months post- treatment, after which routine
follow up data will be collected annually for up to
5 years.
Swallowing assessments A panel of subjective and
objective swallowing outcome measures (Table 2) will
assess swallow function at regular intervals.
Videofluoroscopy sub study
Instrumental swallowing assessment with VF will be per-
formed in approximately 5–10 centres including up to
50 patients. The VF will be conducted by SLTs (with the
required level of competency as set out by the Royal
College of SLT guidelines) supported by a radiographer
and/or radiologist. Central review and rating of images
will be carried out by 2 clinical-academic SLTs (JWGR
and JMP)
Translational sub study
The primary objectives of this planned sub- study
are to obtain DNA and RNA from formalin-fixed,
paraffin- embedded tumour sample for genomic ana-
lysis and to measure and quantify circulating tumour
DNA (ctDNA) at various time points before and
after treatment.
Secondary objectives include the determination of the
sensitivity and specificity of ctDNA in predicting re-
sidual disease following treatment and recurrent disease
during follow- up.
Statistical design
Sample size In a previous cohort of patients treated
with S-IMRT, mean MDADI composite score 12 months
after treatment completion was 72 (SD = 13.8) [4]. A 10-
point improvement in the MDADI composite score at
12 months is considered a clinically relevant outcome
[40]. To have a 90 % power to detect this improvement
(two- sided 5 % significance), 41 patients are required in
each treatment group. Assuming a 20 % drop out due to
disease recurrence, deaths and non-compliance with the
12-month questionnaire, the aim is to recruit 102
patients. MDADI compliance rates will be monitored
regularly to ensure data on 82 evaluable patients are
available.
Up to 50 of the recruited patients (25 in each arm) will
additionally be included in the VF sub study. This will
give 80 % power (one- sided significance 5 %) to detect
an absolute difference of 33 % in the number of patients
experiencing swallowing impairment according to the
Penetration Aspiration Scale (based on 50 % in S-IMRT
vs 17 % in Do-IMRT).
Statistical analysis The primary endpoint will be com-
pared between the two groups using a two-sample t-test
or non-parametric Mann–Whitney test, depending on
distribution of the composite scores. The primary ana-
lysis will be by intention-to-treat, including all patients
with 12 month MDADI data. A p-value of <0.05 will be
considered statistically significant. Analysis of covariance
(ANCOVA) will be used to investigate other patient and
clinical factors that could be associated with change in
MDADI composite score from baseline to 12 months
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post- treatment. Chi-squared or Fisher’s exact test will
be used to compare patients in both groups with
deterioration of 10 points or more in the MDADI com-
posite score.
Interim analysis The anticipated trial recruitment dur-
ation is 2 years and it is therefore unlikely that sufficient
data on the primary endpoint, either for efficacy or futil-
ity, will be available to close the trial early, on that basis
alone. A close monitoring approach will be adopted to
identify loco-regional recurrences (LRR), which will be
reported in an expedited fashion by the treating centre.
The number of LRR from the total number of patients
who commenced trial treatment at that point will be
tabulated by treatment group along with a p-value from
Fisher’s exact test. The Independent Data Monitoring
Committee (IDMC) will use this as guidance together
with other emerging trial data to advise on any early ces-
sation of the trial.
Quality assurance (QA)
Centres taking part in the trial will be required to suc-
cessfully to complete the comprehensive Radiotherapy
Trials Quality Assurance Group (RTTQA) IMRT cre-
dentialing programme in order to be approved to enter
patients. This consists of pre-trial contouring and plan-
ning benchmark cases exercises together with prospect-
ive case reviews for at least the first 2 recruited patients
in each centre [41]. A streamlining process for contour-
ing, aiming to minimise QA repetition, exists for centres
that have participated in other IMRT Head and Neck
trials.
Trial organisation
The DARS trial was developed through a multidisciplin-
ary collaboration between the ICR-CTSU and the Head
and Neck Units of Royal Marsden Hospital NHS Foun-
dation Trust (RMH), University Hospital Bristol, Norfolk
and Norwich University Hospital NHS Trust; Division of
Radiotherapy and Imaging of the Institute of Cancer Re-
search (ICR); Speech and Language Therapy (SLT) De-
partments of RMH, City Hospitals Sunderland NHS
Foundation Trust; Department of Physics of RMH and
RTTQA. ICR-CTSU will have overall responsibility for
trial co-ordination, data collation, central statistical
monitoring of data and all interim analysis. A Trial Man-
agement Group will be responsible for the day to day
running of the trial. The trial will be overseen by an in-
dependent Trial Steering Committee. An IDMC will
regularly review emerging safety and efficacy data in
confidence. The trial is sponsored by RMH and con-
ducted in accordance with the Principles of Good
Clinical Practice. This study is included on the National
Institute for Health Research portfolio (NIHR number
19934).
Discussion
The DARS trial is, to the best of our knowledge, the
first RCT aiming to demonstrate that reducing the
radiation dose to critical swallowing structures can
safely improve long- term swallowing function and
quality of life. The DARS trial design represents the
efforts of a successful collaboration between UK
H&N oncologists, physicists, clinical trialists, and
SLTs, particularly within the context of a H&N pri-
mary CRT trial. Additionally, the association between
clinicians and SLTs, both in DARS and the currently
recruiting PATHOS trial, has huge potential for the
future integration of routine swallowing outcome
measures into UK clinical practice for patients with
HNC. The trial methodology reflects the necessity to
minimise confounding factors that might affect the
Table 2 Functional measures and endpoints
Time point Study Domain Endpoint
Baseline, 3, 6, 12, 18 and
24 months
MDADI Swallowing related QoL Composite (total), global, emotional, functional and physical
subscale scores
Baseline, 3, 6, 12, 18 and
24 months
WST Swallow Performance Swallow capacity, Swallow volume
Baseline, 12 and 24 months VFa Airway protection Penetration Aspiration Scale [52]
Baseline, 12 and 24 months VFa Physiology MBSImp
Baseline, 12 and 24 months VFa Pharyngeal dysphagia grade DIGEST grade [53]
Baseline, 3, 6, 12, 18 and
24 months
PSS-HN Functional Performance
Status
Normalcy of diet, eating in public, understandability of speech
scores
Baseline, 3, 6, 12, 18 and
24 months
UW-Qol
v.04
HR-QoL Composite scores of physical and social-emotional functioning are
derived from 12 domains. Patients can also highlight up to 3 priority
concerns from the previous 7 days
Abbreviations: WST Water Swallowing Test, DIGEST Dynamic Imaging Grade of Swallowing Toxicity, MBSImp Modified Barium Swallow Impairment Profile
aSubset of centres only
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robustness of its final results. Excluding patients
with pre-existing dysphagia ensures that any post-
treatment swallowing dysfunction is as a result of
(chemo)-radiation treatment alone. Likewise, patients
with posterior pharyngeal wall tumours are ineligible
for the trial as any meaningful sparing of the PCM
is unlikely to be achievable. By being selective in our
approach, the trial is better equipped to determine
the effectiveness of Do-IMRT across a homogeneous
group of pharyngeal cancer patients. Defining the
most accurate time point for long-term dysphagia re-
mains controversial within the context of a clinical
trial. Swallow sparing studies have so far adopted
various time points ranging from 3 to 12 months
following completion of treatment [4, 28, 36, 42].
While 3 months is clearly too early to assess long-
term functional outcomes, patterns of swallowing
function can change between 6 and 12 months with
stabilisation thereafter [4, 43], suggesting that the
12- month timeline from treatment completion is
more likely to be predictive of subsequent dysphagia.
The DARS trial recognises the importance of a com-
prehensive assessment for evaluating swallowing by in-
cluding a multidimensional, longitudinal panel of
functional outcome measures integrating instrumental,
clinician- rated and patient- reported scales. The dash-
board of swallowing measures adopted in DARS was
developed in partnership with SLT leads from the
PATHOS trial and should help the standardisation of fu-
ture swallow outcome assessment and reporting. The
MDADI composite score, the primary endpoint of
DARS, is generated from a feasible and validated patient-
reported swallow- specific questionnaire incorporating
information from a patient’s physical, functional and
emotional level at various recovery time points. Increas-
ingly, it is being adopted as functional outcome tool for
a number of head and neck cancer trials [44, 45].
The Do-IMRT is an adaptation of the planning
methodology used by Feng et al. in that it will strive
to spare the part of the pharyngeal constrictors lying
in the elective target volume CTV_5400 rather than
the medial RPN alone (Fig. 2) [46]. A theoretical risk
of increased recurrence in the spared tissue exists
with this approach. It is noteworthy that similar
concerns were raised with the landmark parotid-
sparing IMRT trial (PARSPORT), but these were
proven to be unfounded when the data were ana-
lysed [19]. Furthermore, it is well established that
the majority of the local recurrences following
primary radiation- based treatment are in the imme-
diate vicinity of the primary tumour site (GTV +
1 cm). Importantly, there will be no compromise of
target coverage in this volume with Do-IMRT [47–
50]. Therefore, the risk of recurrence in the spared
tissue is perceived to be minimal. Nevertheless, the
IDMC will closely monitor loco-regional recurrence
rates and advise on early stopping of the trial if this
is deemed necessary. Mean doses to the constrictors
above 50 Gy have previously been shown to be asso-
ciated with the risk of long-term dysphagia [18, 51],
and have consequently been incorporated as the
dosimetric constraint for the PCM within the study.
In conclusion, reducing the risk of late dysphagia
in pharyngeal cancers is vital to improve long-term
HR-QoL. An increased understanding of the clinical
and dosimetric relationship between the swallowing
structures and radiotherapy- related dysphagia, to-
gether with the availability of novel IMRT tech-
niques, makes it an optimal time to run the DARS
trial. The trial is aiming to address the limitations of
previous studies aiming to minimise dysphagia by
testing Do-IMRT in a randomised study, crucially in-
corporating a multidimensional approach to swallow-
ing assessment.
Fig. 2 Tyler et al. [46] PTV_5400 (blue) dose distribution in (a) S- IMRT arm and (b) Do-IMRT, demonstrating sparing of dose to Plan
SMPCM (yellow)
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